메뉴 건너뛰기
Journal of the National Cancer Institute
Volumn 101, Issue 4, 2009, Pages 216-217
Surrogate and mediating endpoints: Current status and future directions
Author keywords

[No Author keywords available]
Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; EDITORIAL; LONG TERM CARE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE; TREATMENT OUTCOME;
EID: 60749096036     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn515     Document Type: Editorial
Times cited : (38)
References (6)
  • 1
    • 0024520844 scopus 로고
    • Surrogate endpoints in clinical trials: Discussion, definition and operational criteria
    • Prentice RL. Surrogate endpoints in clinical trials: discussion, definition and operational criteria. Stat Med. 1989;8(4):431-440.
    • (1989) Stat Med , vol.8 , Issue.4 , pp. 431-440
    • Prentice, R.L.1
  • 2
    • 60749130280 scopus 로고    scopus 로고
    • Potential surrogate endpoints for prostate cancer survival: Analysis of a phase III randomized trial
    • Ray ME, Bae K, Hussain MHA, Hanks GE, Shipley WU, Sandler HM. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst. 2009;101(4):228-236.
    • (2009) J Natl Cancer Inst , vol.101 , Issue.4 , pp. 228-236
    • Ray, M.E.1    Bae, K.2    Hussain, M.H.A.3    Hanks, G.E.4    Shipley, W.U.5    Sandler, H.M.6
  • 3
    • 0030268577 scopus 로고    scopus 로고
    • Surrogate endpoints in clinical trials: Are we being misled?
    • Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.
    • (1996) Ann Intern Med , vol.125 , Issue.7 , pp. 605-613
    • Fleming, T.R.1    DeMets, D.L.2
  • 4
    • 33646443546 scopus 로고    scopus 로고
    • Evaluation of prostate-specific antigen declines for surrogacy in patients treated in SWOG 99-16
    • Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated in SWOG 99-16. J Natl Cancer Inst. 2006;98(8):516-521.
    • (2006) J Natl Cancer Inst , vol.98 , Issue.8 , pp. 516-521
    • Petrylak, D.P.1    Ankerst, D.P.2    Jiang, C.S.3
  • 5
    • 33646441193 scopus 로고    scopus 로고
    • Surrogate endpoints: Wishful thinking or reality?
    • Baker SG. Surrogate endpoints: wishful thinking or reality? J Natl Cancer Inst. 2006;9(8):502-503.
    • (2006) J Natl Cancer Inst , vol.9 , Issue.8 , pp. 502-503
    • Baker, S.G.1
  • 6
    • 60749129880 scopus 로고    scopus 로고
    • Burzykowski T, Molenberghs G, Buyse M, eds, New York, NY: Springer Publishing Co;
    • Burzykowski T, Molenberghs G, Buyse M, eds. The Evaluation of Surrogate Endpoints. New York, NY: Springer Publishing Co; 2005:1-399.
    • (2005) The Evaluation of Surrogate Endpoints , pp. 1-399

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.